FENC:NASDAQFennec Pharmaceuticals Inc. Analysis

Technical outlook: Fennec trades at $6.42, well below its 20‑day ($7.06), 50‑day ($7.71) and 200‑day ($8.18) simple moving averages, with a bearish MACD crossover and an RSI of 40 indicating limited upside momentum. Volume is increasing, but the 30‑day volatility of ~82% and a recent max drawdown of over 40% underscore a high‑risk price environment.
Fundamental outlook: The company posted a 74% YoY revenue surge to $44.6 M and holds a strong gross margin of 92%, yet operating margins remain deeply negative and cash flow is still a net outflow. Forward earnings are projected at $0.91 with a forward P/E of ~7 versus an industry average of 26, suggesting a valuation discount, while a settlement with Cipla delays a generic competitor until 2033, preserving market exclusivity. Recent Q4 earnings missed consensus, delivering a loss of $0.11 per share, but the same period saw a 75% sales increase and a debt‑free balance sheet, providing a mixed but potentially upside‑biased narrative.